ArticleTrials2025
Efficacy of hybrid blood purification for SA-AKI subtypes identified by CCL14: study protocol for a single-centre randomized controlled clinical trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSepsis-associated acute kidney injury (SA-AKI) is a commonly encountered complex heterogeneous syndrome in critically ill patients with sepsis. Under the interaction of genotype and pathogenic factors, SA-AKI can lead to various clinical phenotypes and subphenotypes, and this heterogeneity complicates the assessment of the efficacy of treatment measures for sepsis in clinical trials. Early identification of SA-AKI high-risk patients with specific subphenotypes and timely implementation of supportive treatments may improve adverse outcomes for these patients. High levels of C-C motif chemokine ligand 14 (CCL14) serve as a biomarker that can early identify critically ill patients with persistent SA-AKI. However, the effects of different supportive treatment strategies on the prognosis of SA-AKI patients identified by CCL14 remain unclear. We hypothesize that integrated blood purification (HBP) therapy has a beneficial effect in the treatment of SA-AKI identified by CCL14.
methodsThis is a single-center, blinded, randomized controlled trial. After the patients were admitted to the ICU, blood and urine samples were taken, and the urine CCL14 concentration was measured. Subsequently, they were randomly assigned to the continuous veno-venous hemofiltration (CVVH) group and the hybrid blood purification (HBP) group. The HBP group received blood hemoperfusion (HP) treatment using the HA380 hemoperfusion filter (Jafron, China) and CVVH treatment using the AN69 ST100 blood filter (Baxter, USA). The CVVH group used only the AN69 ST100 blood filter (Baxter, USA) and selected the CVVH mode for continuous renal replacement therapy (CRRT). The primary outcome was the all-cause mortality rate at 30 days after enrollment. The secondary outcomes included the all-cause mortality rate at 90 days, the incidence of chronic kidney disease (CKD) within 90 days, changes in kidney function 72 h after enrollment, variations in endotoxin levels, changes in coagulation function parameters, alterations in inflammatory factor levels, changes in plasma endothelial barrier-related indicators, variations in hemodynamic parameters, changes in SOFA (Sequential (Sepsis-related) Organ Failure Assessment) score, changes in Apache II score, duration of kidney replacement therapy (KRT) during hospitalization, duration of mechanical ventilation, duration of stay in ICU, and duration of stay in hospital. DISCUSSION: This study aims to explore the impact of the HBP therapy on the 30-day all-cause mortality rate of patients with SA-AKI subtypes recognized by CCL14, providing relatively reliable research evidence for determining the optimal treatment approach for patients with persistent severe SA-AKI in clinical practice.
trial registrationChinese Clinical Trial Registry (CHICTR), ChiCTR2400093572. Registered on 9 December 2024, https://www.chictr.org.cn/showproj.html?proj=241688.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.